Filana Therapeutics, Inc. Common Stock (FLNA) Stock Price
FLNAStock
$0.93
Market Cap$44.88M
P/E—
PEG Ratio1.62
Div yield—
Beta1.38
FLNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-11.35%
PEG Ratio1.62
VGM Score56.01
FLNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.18 | +20.00%(+$0.05) | |
| Q1 2026 | -$0.23 | -$0.21 | +8.70%(+$0.02) | |
| Q4 2025 | -$0.30 | -$0.26 | +13.33%(+$0.04) | |
| Q3 2025 | -$0.27 | -$0.22 | +18.52%(+$0.05) | |
| Q2 2025 | — | -$0.92 | — |
FLNA Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.00
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FLNAFilana Therapeutics, Inc. Common Stock | A | — | D | $0.93 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Filana Therapeutics, Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.